Stockscreener 앱 받기
57.17
0.80%
-0.4572
전일 마감가:
$57.63
열려 있는:
$57.635
하루 거래량:
955.12K
Relative Volume:
0.33
시가총액:
$25.45B
수익:
$2.44B
순이익/손실:
$1.36B
주가수익비율:
29.94
EPS:
1.9093
순현금흐름:
$574.14M
1주 성능:
-1.79%
1개월 성능:
-9.42%
6개월 성능:
+17.70%
1년 성능:
+56.67%
1일 변동 폭
$57.02
$57.91
1주일 범위
$57.02
$58.77
52주 변동 폭
$35.23
$64.38
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
57.16 | 25.92B | 2.44B | 1.36B | 574.14M | 1.9093 |
VRTX
Vertex Pharmaceuticals Inc
|
504.92 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
735.89 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
188.19 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
916.91 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.58 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 업그레이드 | UBS | Neutral → Buy |
| 2025-09-30 | 개시 | Goldman | Buy |
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - theglobeandmail.com
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Form 4 Royalty Pharma Plc For: 1 October - Investing.com India
Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 4,126 Shares of Stock - MarketBeat
A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan
4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan
If You Invested $100 In Royalty Pharma Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Operating cash flow per share of Royalty Pharma Plc Class A – HAN:RPD - TradingView
RPD Forecast — Price Target — Prediction for 2027 - TradingView
Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria
RPHC5824522 Bond Profile: Coupon and Redemption - TradingView
Royalty Pharma officer proposes $239K share sale | RPRX SEC FilingForm 144 - Stock Titan
Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Australia
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Eastern Progress
Royalty Pharma (NASDAQ:RPRX) Rating Lowered to Buy at Wall Street Zen - MarketBeat
Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India
Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada
Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com
Royalty Pharma plc (RPRX) stock price, news, quote and history - Yahoo Finance Singapore
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts - MarketBeat
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? - The Motley Fool
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,853,000.00 in Stock - MarketBeat
A prearranged plan governed SCH Investment Partners’ sale of 100,000 Royalty Pharma (RPRX) shares. - Stock Titan
Royalty Pharma plc (RPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
RPHC5237354 Bond Profile: Coupon and Redemption - TradingView
Royalty Pharma PLC (RPD) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q2 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma PLC (RPD) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
RPRX: Strategic AI, scalable deal models, and China expansion drive robust, diversified growth - TradingView
Royalty Pharma PLC (RPD) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma at Bank of America Global Healthcare Conference: growth even with policy risks - Investing.com Nigeria
Royalty Pharma (RPRX) Stock Looks Richly Priced After Its 136% Run - Yahoo Finance
Price-Driven Insight from (RPRX) for Rule-Based Strategy - Stock Traders Daily
Royalty Pharma (RPRX) Could Be 10% Undervalued As Conference Spotlight Returns - Yahoo Finance
Andra AP fonden Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC (RPD) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Royalty Pharma (RPRX) holder plans new sale after selling 350,000 shares - Stock Titan
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
0.15%
자본화:
|
볼륨(24시간):